Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations
Open Access
- 17 July 2019
- Vol. 125 (17), 2910-2914
- https://doi.org/10.1002/cncr.32197
Abstract
Papillary craniopharyngiomas (PCPs) are characterized by the presence of BRAF V600E mutations, which are emerging as a useful guide for diagnosis and treatment decision making. The ongoing multicenter phase 2 Alliance A071601 trial is evaluating the efficacy of BRAF and mitogen‐activated protein kinase kinase (MEK) inhibitors for patients with PCPs. With continued successful responses, it is proposed that BRAF (and MEK) inhibitors be evaluated for the neoadjuvant treatment of patients with PCPs.Keywords
Funding Information
- National Institutes of Health (U54CA225088, 1R01CA227156‐01)
This publication has 19 references indexed in Scilit:
- Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging featuresJournal of Neurosurgery, 2018
- Rathke's Cleft Cyst as Origin of a Pediatric Papillary CraniopharyngiomaFrontiers in Genetics, 2018
- Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapyActa Neurochirurgica, 2017
- BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitorsCNS Oncology, 2017
- Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trialThe Lancet Oncology, 2016
- Consequences of Craniopharyngioma Surgery in ChildrenJournal of Clinical Endocrinology & Metabolism, 2011
- Modern radiotherapy approaches in the management of craniopharyngiomasJournal of Clinical Neuroscience, 2011
- Craniopharyngiomas: an updateExpert Review of Anticancer Therapy, 2006
- Risk Factors for the Development of Obesity in Children Surviving Brain TumorsJournal of Clinical Endocrinology & Metabolism, 2003
- The descriptive epidemiology of craniopharyngiomaJournal of Neurosurgery, 1998